Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00095537 | BMS-599626 in Patients With Advanced Solid Malignancies | PHASE1 | COMPLETED | 60 | — | — | Mar 1, 2004 | - | Mar 2, 2010 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Phase 1 MTD Study | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| panHer | DRUG | Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached. |
Inclusion Criteria: * Diagnosis of metastatic cancer that has progressed on currently available therapies; * At least 3 month life expectancy; * Primary cancer must be solid (non-hematologic); * Adequate bone marrow, liver \& kidney function; * Negative pregnancy test. Exclusion Criteria: * Serio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |